Sir richard sykes net worth
- Sir richard sykes assassination
- Sir Richard Brook Sykes FRS FMedSci HonFREng (born 7 August 1942) is a British microbiologist, the chair of the Royal Institution, the UK Stem Cell Foundation.
- Early life.
- •
Sir Richard Sykes is the Chairman of King Edward VII's Hospital since 2019, Chairman of UK Stem Cell Foundation since 2004. He is a Non-Executive Director of PDS Biotechnology (PDSB) since 2012. He is the President of the Research and Development Society since 2002 and the Chancellor of Brunel University since 2013 to December 2022. He is a member of the joint Advisory Board for the Grantham Institute at Imperial College London and the Grantham Research Institute at LSE since 2021.
Amongst other roles held, Sir Richard Sykes was the Chair of the UK Government Vaccine Task Force from 2021 to 2022 (September), Chairman of the Singapore Biomedical Sciences International Advisory Council from 2000-2022 (March), a mentor at the Chairman Mentors international (CMi) from 2005 to 2021, Chairman of Imperial College Healthcare NHS Trust from 2012 to 2018, Director at Economic Development Board International (EDBI) Pte Ltd Singapore from 2011 to June 2018, Chairman of the Royal Institution of Great Britain from 2010 to 2022 (May), Chairman of NetScientific plc from 2010 to 2019, Chairman o
- •
Richard Sykes
Richard Sykes (Sir Richard Sykes), born 7 August 1942, is currently chancellor of Brunel University. He has had a career spanning science, education and business, holding many high level positions. On his appointment at Brunel David Finlayson, deputy chair of Brunel council described him as a “distinguished leader of an academic institution and a captain of industry with a global view.” Sir Richard described Brunel as a university with “a great brand.” [1]
Sir Richard received a Knighthood in the 1994 New Year's Honours list for services to the pharmaceutical industry. [2]
He is current chairman of the Royal Institution and a fellow of the Royal Society. [3]
He is also chairman of Imperial College Healthcare NHS Trust. [4]
Imperial College London
During his time as vice-chancellor at Imperial, Sykes oversaw the university’s move to independence. He established the centrally managed College Fund and led fundraising schemes such as the flotation of Imperial Innovations as well as a £50 million unsecured private placement
- •
Richard Sykes (microbiologist)
British microbiologist (born 1942)
Sir Richard Brook SykesFRS FMedSci HonFREng (born 7 August 1942) is a British microbiologist, the chair of the Royal Institution, the UK Stem Cell Foundation, and the trustees at King Edward VII's Hospital, and chancellor of Brunel University. As of June 2021, he is chair of the UK's Vaccine Taskforce, where he is responsible for overseeing the delivery of the COVID-19 vaccination programme, including preparations for booster programmes and encouraging vaccine innovation in the UK.
In 1972, after gaining a first class bachelor's degree and a doctorate, both in microbiology, Sykes was appointed head of the Antibiotic Resistance Unit at Glaxo, where he helped develop the antibiotic ceftazidime. Subsequently, he was recruited by the Squibb Institute, in the United States, where he then developed aztreonam, the first clinically effective monobactam, a term he coined in 1981 to describe a new group of monocyclic β-lactams produced by bacteria. He oversaw the merger of Glaxo with Wellcome, to form Glaxo-We
Copyright ©tubglen.pages.dev 2025